...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >Liver X receptor agonist T0901317 reduces neuropathological changes and improves memory in mouse models of experimental dementia
【24h】

Liver X receptor agonist T0901317 reduces neuropathological changes and improves memory in mouse models of experimental dementia

机译:肝X受体激动剂T0901317在实验性痴呆小鼠模型中减少神经病理变化并改善记忆

获取原文
获取原文并翻译 | 示例
           

摘要

The present study has been undertaken to explore the potential of liver X receptor (LXR) modulator, T0901317, in dementia induced by streptozotocin (STZ) and cholesterol enriched diet. Streptozotocin [STZ, 3 mg/kg, injected intracerebroventricular (i.cv.)] and high fat diet (HFD, administered for 90 days) were used to induce dementia in separate groups of Swiss albino mice. The Morris water maze (MWM) test was used to evaluate the effect on cognitive functions. Brain homogenate was used to perform a series of biochemical studies such as, estimation of brain reduced glutathione (GSH), thiobarbituric acid reactive species (TBARS), acetylcholinestrase (AChE) activity and myeloperoxidase (MPO) levels. Serum cholesterol was also determined. STZ and HFD produced a significant decline in MWM performance of the animals, reflecting impairment of learning and memory. STZ/HFD treated mice exhibited a noticeable accentuation of AChE activity, TBARS and MPO levels along with reduction in GSH level. Further the stained micrographs of STZ/HFD treated mice indicated pathological changes, severe neutrophilic infiltration and amyloid deposition. T0901317 treatment significantly attenuated STZ and HFD-induced memory deficits, biochemical and histopathological alterations as well as HFD induced rise in cholesterol content. Hence the study indicates the potential role of liver X receptors in the pathophysiology of dementia. Therefore, the results demonstrate the defensive role of T0901317 in memory dysfunctions which may probably be attributed to its anti-cholinesterase, anti-oxidative, anti-inflammatory and cholesterol lowering effects.
机译:本研究已经进行了探索,以通过链脲佐菌素(STZ)和富含胆固醇的饮食诱导的肝X受体(LXR)调节剂T0901317在痴呆中的潜力。链脲佐菌素[STZ,3 mg / kg,脑室内注射(i.cv.)]和高脂饮食(HFD,给予90天)被用于诱导瑞士白化病小鼠各组的痴呆。莫里斯水迷宫(MWM)测试用于评估对认知功能的影响。脑匀浆用于进行一系列生化研究,例如,脑还原谷胱甘肽(GSH),硫代巴比妥酸反应性物种(TBARS),乙酰胆碱酯酶(AChE)活性和髓过氧化物酶(MPO)水平的估算。还测定了血清胆固醇。 STZ和HFD导致动物的MWM性能显着下降,反映了学习和记忆能力下降。 STZ / HFD处理的小鼠表现出明显的AChE活性,TBARS和MPO水平增强以及GSH水平降低。此外,经STZ / HFD处理的小鼠的染色显微照片表明病理变化,严重的中性粒细胞浸润和淀粉样蛋白沉积。 T0901317处理可显着减轻STZ和HFD引起的记忆缺陷,生化和组织病理学改变以及HFD引起的胆固醇含量上升。因此,该研究表明肝X受体在痴呆症的病理生理中的潜在作用。因此,结果表明T0901317在记忆功能障碍中具有防御作用,这可能归因于其抗胆碱酯酶,抗氧化,抗炎和降低胆固醇的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号